AB0712 DISEASE CONTROL AND QUALITY OF LIFE IN PATIENTS WITH ANKYLOSING SPONDYLITIS AND PSORIATIC ARTHRITIS IN REAL CLINICAL PRACTICE IN SPAIN: MIDAS STUDY
Authors: J. L. Pablos, C. Fernández-Carballido, X. Juanola, J. Gratacos-Masmitja, E. De Miguel, R. Ariza-Ariza, C. Sanabra, P. Terradas, C. Sastré
Journal: Annals of the Rheumatic Diseases (2020)

Background: There are few data on disease activity status and Quality of Life (QoL) in clinical practice in Spain for patients with ankylosing spondylitis (AS) and psoriatic arthritis (PsA). Objectives: To assess the disease activity status in standard clinical practice through BASDAI&lt;4 in AS and DAPSA≤14 in PsA and the relationship with QoL. Methods: An observational, non-interventional, cross-sectional, multicenter study. Patients ≥18 years with ≥6 months diagnosis and classified by ASAS and modified New York criteria or CASPAR criteria undergoing treatment ≥3 months. At the cross-sectional visit, the principal variable taken was the percentage of patients under remission and low disease activity according to the national and European recommendations1-3, assessed through BASDAI and ASDAS-CRP in AS or DAPSA and MDA in PsA. The relationship between patients’ QoL and disease activity were assessed using ASAS-HI in AS and PSAID in PsA. Results: 313 AS patients were included, 75.7% male, 78.5% HLA-B*27+, with a mean (SD) age of 50.4 (12.0) years, a mean (SD) disease duration of 15.5 (11.6) years and a mean (SD) CRP of 5.1 (8.2) mg/l. 313 PsA patients were included, 54.3% male, 17.95% HLA-B*27+, with a mean (SD) age of 54.1 (12.2) years, a mean (SD) disease duration of 10.5 (9.0) years and a mean (SD) CRP of 4.91 (7.3) mg/l. 29.7% AS patients were on biological and 26.8% were on non-biological therapy vs 17.9% and 40.9% PsA patients, respectively. According to BASDAI, 64.5% AS patients were on LDA and 29.4% PsA patients had inactive disease by ASDAS-CRP, 59.4% of patients had a DAPSA&lt;14 while 19,8% were on remission also by DAPSA. In both groups, the QoL impact was low, mean 5.8 in ASAS-HI by AS and 3.0 by PSAID in PsA. QoL impact was significantly higher in patients with active disease (9.3 in AS and 4.4 in PsA). Conclusion: Our observations show that most AS and PsA patients have an inactive disease, whereas 36% and 41% of AS and PsA patients, respectively, are inadequately controlled despite therapy in standard clinical practice in Spain, which is associated to a significantly worse QoL. References: [1]Torre Alonso JC et al. Reumatol Clin 2018;14:254-68 [2]Smolen JS et al. Ann Rheum Dis 2018;77:3-17 [3]Gratacós J et al. Reumatol Clin 2018;14:320-33 Table 1. AS and PsA scores according to the current treatment. Valid N Mean (SD) 95% (CI) AS Disease control (BASDAI) Not under remission (BASDAI&lt;4) 111 9.3 (3.7) (8.6; 10.0) Under remission (BASDAI≥4) 202 3.9 (3.4) (3.4; 4.4) Total 313 5.8 (4.4) (5.3; 6.3) Disease activity (ASDAS-CRP) ASDAS-CRP≥1.3 221 7.1 (4.1) (6.6; 7.7) ASDAS-CRP&lt;1.3 92 2.7 (3.4) (2.0; 3.4) Total 313 5.8 (4.4) (5.3; 6.3) PsA Disease control (DAPSA) Not under remission (DAPSA&gt;14) 127 4.5 (2.4) (4.1; 4.9) Under remission (DAPSA≤14) 186 1.9 (1.7) (1.7; 2.2) Total 313 3.0 (2.4) (2.7; 3.2) Active disease (MDA) Inactive (MDA criteria ≥5) 161 1.5 (1.4) (1.3; 1.7) Active (does not meet MDA criteria) 152 4.5 (2.2) (4.2; 4.8) Total 313 3.0 (2.4) (2.7; 3.2) Acknowledgments: MIDAS group Disclosure of Interests: José L. Pablos Consultant of: Pfizer, Lilly, Novartis, Roche, Celgene, Sanofi, Gilead, Biogen, Paid instructor for: Bristol, Speakers bureau: Abbvie, Janssen, Pfizer, Lilly, Novartis, Roche, Celgene, Bristol, Sanofi, Cristina Fernández-Carballido Consultant of: Yes, I have received fees for scientific advice (Abbvie, Celgene, Janssen, Lilly and Novartis), Speakers bureau: Yes, I have received fees as a speaker (Abbvie, Celgene, Janssen, Lilly, MSD, Novartis), Xavier Juanola Consultant of: Pfizer, Lilly, Novartis, Roche, Celgene, Sanofi, Gilead, Biogen, Paid instructor for: Bristol, Speakers bureau: Abbvie, Janssen, Pfizer, Lilly, Novartis, Roche, Celgene, Bristol, Sanofi, Jordi Gratacos-Masmitja Grant/research support from: a grant from Pfizzer to study implementation of multidisciplinary units to manage PSA in SPAIN, Consultant of: Pfizzer, MSD, ABBVIE, Janssen, Amgen, BMS, Novartis, Lilly, Speakers bureau: Pfizzer, MSD, ABBVIE, Janssen, Amgen, BMS, Novartis, Lilly, Eugenio de Miguel Grant/research support from: Yes (Abbvie, Novartis, Pfizer), Consultant of: Yes (Abbvie, Novartis, Pfizer), Paid instructor for: yes (AbbVie, Novartis, Pfizer, MSD, BMS, UCB, Roche, Grunental, Janssen, Sanofi), Speakers bureau: yes (AbbVie, Novartis, Pfizer, MSD, BMS, UCB, Roche, Grunental, Janssen, Sanofi), Rafael Ariza-Ariza: None declared, Cristina Sanabra Employee of: Yes: employed as a Medical Advisor (Novartis), Pau Terradas Employee of: Yes: employed as a Medical Advisor (Novartis), Carlos Sastré Employee of: YES; I´m Medical Advisor in Novartis Spain